Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.71 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.71 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.71 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL25333179 | 0.97 | OR51E2 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL25331377 | 0.97 | GLRA1 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL25362123 | 0.97 | OR51E2 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL2586653 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL978830 | 0.93 | GLRA1 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL583138 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL978831 | 0.93 | GLRA1 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL25330893 | 0.91 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL22518912 | 0.90 | GLRA1 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL5961782 | 0.90 | GLRA1 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3913 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736846-A1 | TABLET COMPOSITION COMPRISING BREXPIPRAZOLE OR A SALT THEREOF | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2026-05-06 | — | — | EP | claimed |
| EP-4727528-A1 | A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2026-04-22 | — | — | EP | claimed |
| EP-4729053-A1 | SOLID DISPERSION OF P2X4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan Createrna Science and Technology Co.,Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4702113-A1 | A SOLID DISINFECTION COMPOSITION | Unilever IP Holdings B.V. (NL) | 2026-03-04 | — | — | EP | claimed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | claimed |
| EP-4663186-A1 | A TABLET COMPOSITION COMPRISING BENIDIPINE | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2025-12-17 | — | — | EP | claimed |
| US-20250332107-A1 | IMMEDIATE RELEASE DOSAGE FORM | KENVUE BRANDS LLC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4620522-A2 | A COMBINATION COMPRISING VILDAGLIPTIN AND METFORMIN | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2025-09-24 | — | — | EP | claimed |
| WO-1991015197-A1 | PHARMACEUTICAL FORMULATION | BEECHAM GROUP PLC (GB) | 1991-10-17 | — | — | WO | claimed |
| EP-0293975-B1 | DRY, RAPIDLY SOLUBLE, COMPOSITIONS OF BETA-LACTAM ANTIBIOTICS | AKZO N.V. (NL) | 1991-07-24 | — | — | EP | claimed |
| EP-0396335-A1 | Pharmaceutical formulation | Beecham Group p.l.c. (GB) | 1990-11-07 | — | — | EP | claimed |
| EP-0363569-A1 | Spontaneously water-dispersible composition particularly suitable for treating the skin | COMPAGNA ITALIANA SALI C.I.S. S.p.A. (IT) | 1990-04-18 | — | — | EP | claimed |
| EP-0293975-A1 | Dry, rapidly soluble, compositions of beta-lactam antibiotics | AKZO N.V. (NL) | 1988-12-07 | — | — | EP | claimed |
| WO-1988009173-A1 | DRY, RAPIDLY SOLUBLE, COMPOSITIONS OF beta-LACTAM ANTIBIOTICS | AKZO N.V. (NL) | 1988-12-01 | — | — | WO | claimed |
| US-4532253-A | Oxaprozin calcium salt pharmaceutical compositions | JOHN WYETH & BROTHER LIMITED (GB) | 1985-07-30 | — | — | US | claimed |
| EP-0063884-B1 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND USE | JOHN WYETH & BROTHER LIMITED (GB) | 1985-06-26 | — | — | EP | claimed |
| EP-0063884-A1 | Oxazole derivatives, their preparation and use | JOHN WYETH & BROTHER LIMITED (GB) | 1982-11-03 | — | — | EP | claimed |
| US-RE29102-E | Contraception agent | MERZ & CO. (DT) | 1977-01-04 | — | — | US | claimed |